94. 原発性硬化性胆管炎 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 148 / 薬物数 : 118 - (DrugBank : 39) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 141
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
11C-CSar
University of Aarhus
2013 Phase 1 NCT01879735 Denmark;
3108006977
RIEMSER Arzneimittel AG
2005 - EUCTR2005-001454-24-LT Lithuania;
ACIDO DEOSSICOLICO
DR. FALK PHARMA GMBH
2018 Phase 3 EUCTR2016-003367-19-IT Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;
ACIDO OBETICOLICO
INTERCEPT PHARMACEUTICALS INC.
2015 Phase 2 EUCTR2014-002205-38-IT Italy;United States;
AZT
Tajiri Hitoshi
2012 Phase 2 JPRN-jRCTs051180120 Japan;
All-trans retinoic acid
Yale University
2018 Phase 2 NCT03359174 United States;
Azathioprine
Osaka General Medical Center
2012 - JPRN-UMIN000029482 Japan;
Tajiri Hitoshi
2012 Phase 2 JPRN-jRCTs051180120 Japan;
BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2020 Phase 3 EUCTR2019-001015-23-FR France;
BTT1023
University of Birmingham
2015 Phase 2 NCT02239211 United Kingdom;
BTT1023 IV Infusion 20 mg/mL, 5 mL Drug Product
University of Birmingham
2015 Phase 2 EUCTR2014-002393-37-GB United Kingdom;
Bezafibrate
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2016 Phase 3 NCT02701166 Netherlands;Spain;
Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy
Assistance Publique - Hôpitaux de Paris
2021 Phase 3 NCT04309773 France;
Bezalip
Academic Medical Center
2017 Phase 2 EUCTR2014-001438-27-ES Netherlands;Spain;
2015 - EUCTR2014-001438-27-NL Netherlands;
Budesonide
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1997 Phase 1 NCT00004842 United States;
C10AB02
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2020 Phase 3 EUCTR2019-001015-23-FR France;
CILO
Gilead Sciences
2019 Phase 1 NCT04060147 United States;
CM-101
ChemomAb Ltd
2022 Phase 2 EUCTR2019-002945-39-ES Israel;Spain;United Kingdom;
2020 Phase 2 EUCTR2019-002945-39-GB Israel;United Kingdom;
ChemomAb Ltd.
2020 Phase 2 NCT04595825 Germany;Israel;United Kingdom;
2019 Phase 2 EUCTR2018-004258-77-GB Israel;United Kingdom;
CS0159
Cascade Pharmaceuticals, Inc
2021 Phase 1 NCT05082779 United States;
Capecitabine
Azienda Ospedaliera di Padova
2012 - NCT01549795 Italy;
Cenicriviroc
Tobira Therapeutics, Inc.
2016 Phase 2 NCT02653625 Canada;United States;
Cilofexor
GILEAD SCIENCES INCORPORATED
2019 Phase 3 EUCTR2019-000204-14-IT Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
Gilead Sciences
2019 Phase 3 NCT03890120 Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;New Zealand;Spain;Switzerland;United Kingdom;United States;
2016 Phase 2 NCT02943460 Austria;Canada;United Kingdom;United States;
2016 Phase 1 NCT02808312 New Zealand;United States;
Gilead Sciences, Inc.
2019 Phase 3 EUCTR2019-000204-14-GB Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000204-14-FR Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000204-14-FI Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000204-14-ES Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000204-14-DK Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000204-14-AT Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
Cis-4-Hydroxy-L-Proline
RIEMSER Arzneimittel AG
2005 - EUCTR2005-001454-24-LT Lithuania;
Cladribine
National Center for Research Resources (NCRR)
1994 Phase 2 NCT00004762 -
Curcumin
John E. Eaton
2017 Phase 1/Phase 2 NCT02978339 United States;
DUR-928
Durect
2018 Phase 2 NCT03394781 United States;
Docosahexaenoic Acid (DHA)
Beth Israel Deaconess Medical Center
2005 Phase 1 NCT00325013 United States;
Engineered recombinant human FGF19
NGM Biopharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-003392-30-NL France;Netherlands;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003392-30-GB France;Netherlands;United Kingdom;United States;
Entyvio
TAKEDA DEVELOPMENT CENTRE EUROPE LTD
2016 Phase 3 EUCTR2014-003942-28-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
Takeda Development Centre Europe, Ltd.
2016 Phase 3 EUCTR2014-003942-28-SE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-DE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
Erlotinib (Tarceva)
Mayo Clinic
2009 Phase 1 NCT00955149 United States;
FLUIMUCIL*20CPR EFF
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
2012 - EUCTR2012-004170-26-IT Italy;
Fecal Microbiota Transplantation
Brigham and Women's Hospital
2016 Phase 1/Phase 2 NCT02424175 United States;
Fenofibrate
University of Miami
2010 Phase 1/Phase 2 NCT01142323 United States;
GS-6624
Gilead Sciences Inc
2013 Phase 2 EUCTR2012-002473-61-SE Belgium;Canada;Denmark;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 2 EUCTR2012-002473-61-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 2 EUCTR2012-002473-61-IT Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 2 EUCTR2012-002473-61-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 2 EUCTR2012-002473-61-ES Belgium;Canada;Denmark;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 2 EUCTR2012-002473-61-DK Belgium;Canada;Denmark;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 2 EUCTR2012-002473-61-DE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 2 EUCTR2012-002473-61-BE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
GS-9674
GILEAD SCIENCES INCORPORATED
2019 Phase 3 EUCTR2019-000204-14-IT Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
Gilead Sciences, Inc.
2019 Phase 3 EUCTR2019-000204-14-GB Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000204-14-FR Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000204-14-FI Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000204-14-ES Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000204-14-DK Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000204-14-AT Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2 EUCTR2016-002442-23-GB Austria;Canada;United Kingdom;United States;
2017 Phase 2 EUCTR2016-002442-23-AT Austria;Canada;United Kingdom;United States;
Gluten-free diet
Universitätsklinikum Hamburg-Eppendorf
2017 - NCT04006886 Germany;
HTD1801
HighTide Biopharma Pty Ltd
2021 Phase 2 NCT03678480 -
2018 Phase 2 NCT03333928 Canada;United States;
2017 Phase 1 NCT03099603 Australia;
Humanised IgG1 monoclonal antibody against human eotaxin-2
ChemomAb Ltd
2022 Phase 2 EUCTR2019-002945-39-ES Israel;Spain;United Kingdom;
2020 Phase 2 EUCTR2019-002945-39-GB Israel;United Kingdom;
ICG
University of Aarhus
2013 Phase 1 NCT01879735 Denmark;
INT-747, OCA
INTERCEPT PHARMACEUTICALS INC.
2015 Phase 2 EUCTR2014-002205-38-IT Italy;United States;
LUM001
Lumena Pharmaceuticals LLC
2015 Phase 2 EUCTR2014-005558-21-GB United Kingdom;United States;
Mirum Pharmaceuticals, Inc.
2014 Phase 2 NCT02061540 Canada;United Kingdom;United States;
MBX-8025
CymaBay Therapeutics
2019 Phase 2 EUCTR2019-001760-30-PL Australia;Canada;Germany;Israel;Poland;United Kingdom;United States;
2019 Phase 2 EUCTR2019-001760-30-GB Australia;Canada;Germany;Israel;Poland;United Kingdom;United States;
MLN0002
Takeda Development Centre Europe, Ltd.
2016 Phase 3 EUCTR2014-003942-28-SE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-DE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
Metronidazole
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2016 - NCT03069976 Belgium;
Keio University, School of Medicine
2016 - JPRN-UMIN000021411 Japan;
Mayo Clinic
2010 Phase 1 NCT01085760 United States;
Minocycline
Mayo Clinic
2003 Phase 1 NCT00630942 United States;
Mitomycin C
Li, Zhiping, M.D.
2012 Phase 2 NCT01688024 United States;
Mizoribine
Osaka General Medical Center
2012 - JPRN-UMIN000029482 Japan;
Tajiri Hitoshi
2012 Phase 2 JPRN-jRCTs051180120 Japan;
NGM282
NGM Biopharmaceuticals, Inc
2016 Phase 2 NCT02704364 France;Netherlands;United Kingdom;United States;
NGM Biopharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-003392-30-NL France;Netherlands;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003392-30-GB France;Netherlands;United Kingdom;United States;
NorUDCA
Dr. Falk Pharma GmbH
2019 Phase 3 EUCTR2016-003367-19-NL Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Lithuania;Netherlands;Poland;Sweden;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-003367-19-PL Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-003367-19-GB Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-003367-19-FR Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Lithuania;Netherlands;Poland;Sweden;Switzerland;United Kingdom;
2017 Phase 3 EUCTR2016-003367-19-LT Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2017 Phase 3 EUCTR2016-003367-19-HU Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2014 - EUCTR2011-002754-31-BE Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
2013 Phase 2 EUCTR2011-002754-31-GB Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
2012 Phase 2 NCT01755507 Austria;Germany;Norway;
2012 Phase 2 EUCTR2011-002754-31-SE Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
2012 Phase 2 EUCTR2011-002754-31-NO Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
2012 - EUCTR2011-002754-31-NL Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
2012 - EUCTR2011-002754-31-LT Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
2012 - EUCTR2011-002754-31-HU Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
2012 - EUCTR2011-002754-31-FI Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
2012 - EUCTR2011-002754-31-ES Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
2012 - EUCTR2011-002754-31-DK Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
2012 - EUCTR2011-002754-31-DE Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
2012 - EUCTR2011-002754-31-AT Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2016-003367-19-IE Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Lithuania;Netherlands;Poland;Sweden;Switzerland;United Kingdom;
NorUDCA (Norursodeoxycholic acid)
DR. FALK PHARMA GMBH
2018 Phase 3 EUCTR2016-003367-19-IT Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;
Normal saline
Li, Zhiping, M.D.
2012 Phase 2 NCT01688024 United States;
Norucholic acid
Dr. Falk Pharma GmbH
2018 Phase 3 EUCTR2016-003367-19-SE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-003367-19-FI Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-003367-19-DK Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-003367-19-CZ Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-003367-19-BE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2017 Phase 3 EUCTR2016-003367-19-DE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2017 Phase 3 EUCTR2016-003367-19-AT Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
- Phase 3 EUCTR2016-003367-19-NO Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
Norursodeoxycholic acid, NCA
Dr. Falk Pharma GmbH
2018 Phase 3 EUCTR2016-003367-19-SE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-003367-19-FI Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-003367-19-DK Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-003367-19-CZ Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-003367-19-BE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2017 Phase 3 EUCTR2016-003367-19-DE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2017 Phase 3 EUCTR2016-003367-19-AT Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
- Phase 3 EUCTR2016-003367-19-NO Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
OCA
Intercept Pharmaceuticals
2015 Phase 2 NCT02177136 Austria;Belgium;France;Germany;Italy;Netherlands;Norway;Sweden;United Kingdom;United States;
OCA 1,
INTERCEPT PHARMACEUTICALS INC.
2015 Phase 2 EUCTR2014-002205-38-IT Italy;United States;
Oral Vancomycin
Sacramento Pediatric Gastroenterology
2010 Phase 1 NCT02137668 United States;
Stanford University
2012 Phase 3 NCT01802073 United States;
Oral all-trans retinoic acid (ATRA)
Yale University
2011 Phase 1 NCT01456468 United States;
Orbcel-C
University of Birmingham
2018 Phase 1/Phase 2 NCT02997878 United Kingdom;
PLN-74809
Pliant Therapeutics, Inc
2021 Phase 2 EUCTR2020-001428-33-NL Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Norway;United Kingdom;United States;
2021 Phase 2 EUCTR2020-001428-33-DE Australia;Austria;Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States;
2020 Phase 2 EUCTR2020-001428-33-GB Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Norway;United Kingdom;United States;
Pliant Therapeutics, Inc.
2020 Phase 2 NCT04480840 Australia;Austria;Belgium;Canada;Germany;Netherlands;United Kingdom;United States;
Phenylbutyrate
Juntendo University
2014 - JPRN-UMIN000012782 Japan;
Saiseikai Yokohama City Tobu Hospital
2010 - JPRN-UMIN000003802 Japan;
Pre liver transplantation laparoscopic hand assisted staging
Azienda Ospedaliera di Padova
2012 - NCT01549795 Italy;
Probiotics
UMC Utrecht
2005 Phase 3 NCT00161148 Netherlands;
Rec-h-FGF19
NGM Biopharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-003392-30-NL France;Netherlands;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003392-30-GB France;Netherlands;United Kingdom;United States;
Rituximab
Keio University Hospital
2016 - JPRN-UMIN000022897 Japan;
Seladelpar
CymaBay Therapeutics, Inc.
2019 Phase 2 NCT04024813 Canada;Poland;United States;
Simtuzimab
Gilead Sciences Inc
2013 Phase 2 EUCTR2012-002473-61-IT Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Simtuzumab
Gilead Sciences
2013 Phase 2 NCT01672853 Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Gilead Sciences Inc
2013 Phase 2 EUCTR2012-002473-61-IT Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Simvastatin
Annika Bergquist
2020 Phase 3 NCT04133792 Sweden;
Sulfasalazine
Brigham and Women's Hospital
2018 Phase 2 NCT03561584 United States;
TBC
ChemomAb Ltd
2022 Phase 2 EUCTR2019-002945-39-ES Israel;Spain;United Kingdom;
2020 Phase 2 EUCTR2019-002945-39-GB Israel;United Kingdom;
Thalidomide
Mayo Clinic
2006 Phase 2 NCT00953615 United States;
UCMSC
Fuzhou General Hospital
2017 Phase 1/Phase 2 NCT03516006 -
UDCA
Fuzhou General Hospital
2017 Phase 1/Phase 2 NCT03516006 -
Ursodeoxycholic acid (UDCA)
University of Tennessee
2010 Phase 1 NCT01088607 Canada;United States;
Ursofalk
Sahlgrenska Academy
2015 Phase 3 EUCTR2015-003310-24-SE Sweden;
Ursolic acid
University of California, Davis
2017 Phase 1 NCT03216876 United States;
Vancomycin
Elizabeth Carey
2020 Phase 2/Phase 3 NCT03710122 Canada;United States;
Karolinska Institutet
2013 - EUCTR2009-018034-11-SE Sweden;
Mayo Clinic
2010 Phase 1 NCT01085760 United States;
Ochsner Health System
2016 - NCT03046901 United States;
Stanford University
2007 Phase 1 NCT01322386 -
Tehran University of Medical Sciences
2015 Phase 4 NCT02605213 Iran, Islamic Republic of;
University of Minnesota
2015 Phase 1 NCT02464020 United States;
Vedolizumab
Takeda
2017 Phase 3 NCT03035058 -
Vedolizumab IV
Takeda Development Centre Europe, Ltd.
2016 Phase 3 EUCTR2014-003942-28-SE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-DE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
Vidofludimus calcium
Elizabeth Carey
2019 Phase 2 NCT03722576 United States;
Volixibat
Mirum Pharmaceuticals, Inc.
2020 Phase 2 NCT04663308 United States;
Volixibat (formely SHP626, LUM002 or SAR548304B)
Mirum Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2020-003027-41-DE Canada;Germany;Israel;United Kingdom;United States;
Volixibat potassium
Mirum Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2020-003027-41-DE Canada;Germany;Israel;United Kingdom;United States;
Xifaxan
Mayo Clinic
2012 Phase 1 NCT01695174 United States;
[18F]FP-R01-MG-F2
Stanford University
2017 Early Phase 1 NCT03183570 United States;
University of Aarhus
2013 Phase 1 NCT01879735 Denmark;
3108006977
RIEMSER Arzneimittel AG
2005 - EUCTR2005-001454-24-LT Lithuania;
ACIDO DEOSSICOLICO
DR. FALK PHARMA GMBH
2018 Phase 3 EUCTR2016-003367-19-IT Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;
ACIDO OBETICOLICO
INTERCEPT PHARMACEUTICALS INC.
2015 Phase 2 EUCTR2014-002205-38-IT Italy;United States;
AZT
Tajiri Hitoshi
2012 Phase 2 JPRN-jRCTs051180120 Japan;
All-trans retinoic acid
Yale University
2018 Phase 2 NCT03359174 United States;
Azathioprine
Osaka General Medical Center
2012 - JPRN-UMIN000029482 Japan;
Tajiri Hitoshi
2012 Phase 2 JPRN-jRCTs051180120 Japan;
BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2020 Phase 3 EUCTR2019-001015-23-FR France;
BTT1023
University of Birmingham
2015 Phase 2 NCT02239211 United Kingdom;
BTT1023 IV Infusion 20 mg/mL, 5 mL Drug Product
University of Birmingham
2015 Phase 2 EUCTR2014-002393-37-GB United Kingdom;
Bezafibrate
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2016 Phase 3 NCT02701166 Netherlands;Spain;
Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy
Assistance Publique - Hôpitaux de Paris
2021 Phase 3 NCT04309773 France;
Bezalip
Academic Medical Center
2017 Phase 2 EUCTR2014-001438-27-ES Netherlands;Spain;
2015 - EUCTR2014-001438-27-NL Netherlands;
Budesonide
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1997 Phase 1 NCT00004842 United States;
C10AB02
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2020 Phase 3 EUCTR2019-001015-23-FR France;
CILO
Gilead Sciences
2019 Phase 1 NCT04060147 United States;
CM-101
ChemomAb Ltd
2022 Phase 2 EUCTR2019-002945-39-ES Israel;Spain;United Kingdom;
2020 Phase 2 EUCTR2019-002945-39-GB Israel;United Kingdom;
ChemomAb Ltd.
2020 Phase 2 NCT04595825 Germany;Israel;United Kingdom;
2019 Phase 2 EUCTR2018-004258-77-GB Israel;United Kingdom;
CS0159
Cascade Pharmaceuticals, Inc
2021 Phase 1 NCT05082779 United States;
Capecitabine
Azienda Ospedaliera di Padova
2012 - NCT01549795 Italy;
Cenicriviroc
Tobira Therapeutics, Inc.
2016 Phase 2 NCT02653625 Canada;United States;
Cilofexor
GILEAD SCIENCES INCORPORATED
2019 Phase 3 EUCTR2019-000204-14-IT Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
Gilead Sciences
2019 Phase 3 NCT03890120 Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;New Zealand;Spain;Switzerland;United Kingdom;United States;
2016 Phase 2 NCT02943460 Austria;Canada;United Kingdom;United States;
2016 Phase 1 NCT02808312 New Zealand;United States;
Gilead Sciences, Inc.
2019 Phase 3 EUCTR2019-000204-14-GB Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000204-14-FR Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000204-14-FI Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000204-14-ES Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000204-14-DK Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000204-14-AT Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
Cis-4-Hydroxy-L-Proline
RIEMSER Arzneimittel AG
2005 - EUCTR2005-001454-24-LT Lithuania;
Cladribine
National Center for Research Resources (NCRR)
1994 Phase 2 NCT00004762 -
Curcumin
John E. Eaton
2017 Phase 1/Phase 2 NCT02978339 United States;
DUR-928
Durect
2018 Phase 2 NCT03394781 United States;
Docosahexaenoic Acid (DHA)
Beth Israel Deaconess Medical Center
2005 Phase 1 NCT00325013 United States;
Engineered recombinant human FGF19
NGM Biopharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-003392-30-NL France;Netherlands;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003392-30-GB France;Netherlands;United Kingdom;United States;
Entyvio
TAKEDA DEVELOPMENT CENTRE EUROPE LTD
2016 Phase 3 EUCTR2014-003942-28-IT Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
Takeda Development Centre Europe, Ltd.
2016 Phase 3 EUCTR2014-003942-28-SE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-DE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
Erlotinib (Tarceva)
Mayo Clinic
2009 Phase 1 NCT00955149 United States;
FLUIMUCIL*20CPR EFF
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
2012 - EUCTR2012-004170-26-IT Italy;
Fecal Microbiota Transplantation
Brigham and Women's Hospital
2016 Phase 1/Phase 2 NCT02424175 United States;
Fenofibrate
University of Miami
2010 Phase 1/Phase 2 NCT01142323 United States;
GS-6624
Gilead Sciences Inc
2013 Phase 2 EUCTR2012-002473-61-SE Belgium;Canada;Denmark;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 2 EUCTR2012-002473-61-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 2 EUCTR2012-002473-61-IT Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 2 EUCTR2012-002473-61-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 2 EUCTR2012-002473-61-ES Belgium;Canada;Denmark;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 2 EUCTR2012-002473-61-DK Belgium;Canada;Denmark;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 2 EUCTR2012-002473-61-DE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2013 Phase 2 EUCTR2012-002473-61-BE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
GS-9674
GILEAD SCIENCES INCORPORATED
2019 Phase 3 EUCTR2019-000204-14-IT Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
Gilead Sciences, Inc.
2019 Phase 3 EUCTR2019-000204-14-GB Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000204-14-FR Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000204-14-FI Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000204-14-ES Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000204-14-DK Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000204-14-AT Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2 EUCTR2016-002442-23-GB Austria;Canada;United Kingdom;United States;
2017 Phase 2 EUCTR2016-002442-23-AT Austria;Canada;United Kingdom;United States;
Gluten-free diet
Universitätsklinikum Hamburg-Eppendorf
2017 - NCT04006886 Germany;
HTD1801
HighTide Biopharma Pty Ltd
2021 Phase 2 NCT03678480 -
2018 Phase 2 NCT03333928 Canada;United States;
2017 Phase 1 NCT03099603 Australia;
Humanised IgG1 monoclonal antibody against human eotaxin-2
ChemomAb Ltd
2022 Phase 2 EUCTR2019-002945-39-ES Israel;Spain;United Kingdom;
2020 Phase 2 EUCTR2019-002945-39-GB Israel;United Kingdom;
ICG
University of Aarhus
2013 Phase 1 NCT01879735 Denmark;
INT-747, OCA
INTERCEPT PHARMACEUTICALS INC.
2015 Phase 2 EUCTR2014-002205-38-IT Italy;United States;
LUM001
Lumena Pharmaceuticals LLC
2015 Phase 2 EUCTR2014-005558-21-GB United Kingdom;United States;
Mirum Pharmaceuticals, Inc.
2014 Phase 2 NCT02061540 Canada;United Kingdom;United States;
MBX-8025
CymaBay Therapeutics
2019 Phase 2 EUCTR2019-001760-30-PL Australia;Canada;Germany;Israel;Poland;United Kingdom;United States;
2019 Phase 2 EUCTR2019-001760-30-GB Australia;Canada;Germany;Israel;Poland;United Kingdom;United States;
MLN0002
Takeda Development Centre Europe, Ltd.
2016 Phase 3 EUCTR2014-003942-28-SE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-DE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
Metronidazole
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2016 - NCT03069976 Belgium;
Keio University, School of Medicine
2016 - JPRN-UMIN000021411 Japan;
Mayo Clinic
2010 Phase 1 NCT01085760 United States;
Minocycline
Mayo Clinic
2003 Phase 1 NCT00630942 United States;
Mitomycin C
Li, Zhiping, M.D.
2012 Phase 2 NCT01688024 United States;
Mizoribine
Osaka General Medical Center
2012 - JPRN-UMIN000029482 Japan;
Tajiri Hitoshi
2012 Phase 2 JPRN-jRCTs051180120 Japan;
NGM282
NGM Biopharmaceuticals, Inc
2016 Phase 2 NCT02704364 France;Netherlands;United Kingdom;United States;
NGM Biopharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-003392-30-NL France;Netherlands;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003392-30-GB France;Netherlands;United Kingdom;United States;
NorUDCA
Dr. Falk Pharma GmbH
2019 Phase 3 EUCTR2016-003367-19-NL Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Lithuania;Netherlands;Poland;Sweden;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-003367-19-PL Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-003367-19-GB Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-003367-19-FR Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Lithuania;Netherlands;Poland;Sweden;Switzerland;United Kingdom;
2017 Phase 3 EUCTR2016-003367-19-LT Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2017 Phase 3 EUCTR2016-003367-19-HU Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2014 - EUCTR2011-002754-31-BE Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
2013 Phase 2 EUCTR2011-002754-31-GB Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
2012 Phase 2 NCT01755507 Austria;Germany;Norway;
2012 Phase 2 EUCTR2011-002754-31-SE Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
2012 Phase 2 EUCTR2011-002754-31-NO Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
2012 - EUCTR2011-002754-31-NL Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
2012 - EUCTR2011-002754-31-LT Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
2012 - EUCTR2011-002754-31-HU Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
2012 - EUCTR2011-002754-31-FI Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
2012 - EUCTR2011-002754-31-ES Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
2012 - EUCTR2011-002754-31-DK Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
2012 - EUCTR2011-002754-31-DE Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
2012 - EUCTR2011-002754-31-AT Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
- Phase 3 EUCTR2016-003367-19-IE Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Lithuania;Netherlands;Poland;Sweden;Switzerland;United Kingdom;
NorUDCA (Norursodeoxycholic acid)
DR. FALK PHARMA GMBH
2018 Phase 3 EUCTR2016-003367-19-IT Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;
Normal saline
Li, Zhiping, M.D.
2012 Phase 2 NCT01688024 United States;
Norucholic acid
Dr. Falk Pharma GmbH
2018 Phase 3 EUCTR2016-003367-19-SE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-003367-19-FI Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-003367-19-DK Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-003367-19-CZ Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-003367-19-BE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2017 Phase 3 EUCTR2016-003367-19-DE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2017 Phase 3 EUCTR2016-003367-19-AT Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
- Phase 3 EUCTR2016-003367-19-NO Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
Norursodeoxycholic acid, NCA
Dr. Falk Pharma GmbH
2018 Phase 3 EUCTR2016-003367-19-SE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-003367-19-FI Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-003367-19-DK Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-003367-19-CZ Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2018 Phase 3 EUCTR2016-003367-19-BE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2017 Phase 3 EUCTR2016-003367-19-DE Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2017 Phase 3 EUCTR2016-003367-19-AT Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
- Phase 3 EUCTR2016-003367-19-NO Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
OCA
Intercept Pharmaceuticals
2015 Phase 2 NCT02177136 Austria;Belgium;France;Germany;Italy;Netherlands;Norway;Sweden;United Kingdom;United States;
OCA 1,
INTERCEPT PHARMACEUTICALS INC.
2015 Phase 2 EUCTR2014-002205-38-IT Italy;United States;
Oral Vancomycin
Sacramento Pediatric Gastroenterology
2010 Phase 1 NCT02137668 United States;
Stanford University
2012 Phase 3 NCT01802073 United States;
Oral all-trans retinoic acid (ATRA)
Yale University
2011 Phase 1 NCT01456468 United States;
Orbcel-C
University of Birmingham
2018 Phase 1/Phase 2 NCT02997878 United Kingdom;
PLN-74809
Pliant Therapeutics, Inc
2021 Phase 2 EUCTR2020-001428-33-NL Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Norway;United Kingdom;United States;
2021 Phase 2 EUCTR2020-001428-33-DE Australia;Austria;Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States;
2020 Phase 2 EUCTR2020-001428-33-GB Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Norway;United Kingdom;United States;
Pliant Therapeutics, Inc.
2020 Phase 2 NCT04480840 Australia;Austria;Belgium;Canada;Germany;Netherlands;United Kingdom;United States;
Phenylbutyrate
Juntendo University
2014 - JPRN-UMIN000012782 Japan;
Saiseikai Yokohama City Tobu Hospital
2010 - JPRN-UMIN000003802 Japan;
Pre liver transplantation laparoscopic hand assisted staging
Azienda Ospedaliera di Padova
2012 - NCT01549795 Italy;
Probiotics
UMC Utrecht
2005 Phase 3 NCT00161148 Netherlands;
Rec-h-FGF19
NGM Biopharmaceuticals, Inc.
2016 Phase 2 EUCTR2015-003392-30-NL France;Netherlands;United Kingdom;United States;
2016 Phase 2 EUCTR2015-003392-30-GB France;Netherlands;United Kingdom;United States;
Rituximab
Keio University Hospital
2016 - JPRN-UMIN000022897 Japan;
Seladelpar
CymaBay Therapeutics, Inc.
2019 Phase 2 NCT04024813 Canada;Poland;United States;
Simtuzimab
Gilead Sciences Inc
2013 Phase 2 EUCTR2012-002473-61-IT Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Simtuzumab
Gilead Sciences
2013 Phase 2 NCT01672853 Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Gilead Sciences Inc
2013 Phase 2 EUCTR2012-002473-61-IT Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Simvastatin
Annika Bergquist
2020 Phase 3 NCT04133792 Sweden;
Sulfasalazine
Brigham and Women's Hospital
2018 Phase 2 NCT03561584 United States;
TBC
ChemomAb Ltd
2022 Phase 2 EUCTR2019-002945-39-ES Israel;Spain;United Kingdom;
2020 Phase 2 EUCTR2019-002945-39-GB Israel;United Kingdom;
Thalidomide
Mayo Clinic
2006 Phase 2 NCT00953615 United States;
UCMSC
Fuzhou General Hospital
2017 Phase 1/Phase 2 NCT03516006 -
UDCA
Fuzhou General Hospital
2017 Phase 1/Phase 2 NCT03516006 -
Ursodeoxycholic acid (UDCA)
University of Tennessee
2010 Phase 1 NCT01088607 Canada;United States;
Ursofalk
Sahlgrenska Academy
2015 Phase 3 EUCTR2015-003310-24-SE Sweden;
Ursolic acid
University of California, Davis
2017 Phase 1 NCT03216876 United States;
Vancomycin
Elizabeth Carey
2020 Phase 2/Phase 3 NCT03710122 Canada;United States;
Karolinska Institutet
2013 - EUCTR2009-018034-11-SE Sweden;
Mayo Clinic
2010 Phase 1 NCT01085760 United States;
Ochsner Health System
2016 - NCT03046901 United States;
Stanford University
2007 Phase 1 NCT01322386 -
Tehran University of Medical Sciences
2015 Phase 4 NCT02605213 Iran, Islamic Republic of;
University of Minnesota
2015 Phase 1 NCT02464020 United States;
Vedolizumab
Takeda
2017 Phase 3 NCT03035058 -
Vedolizumab IV
Takeda Development Centre Europe, Ltd.
2016 Phase 3 EUCTR2014-003942-28-SE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-PL Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-HU Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-GB Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-DE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-BE Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2014-003942-28-AT Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
Vidofludimus calcium
Elizabeth Carey
2019 Phase 2 NCT03722576 United States;
Volixibat
Mirum Pharmaceuticals, Inc.
2020 Phase 2 NCT04663308 United States;
Volixibat (formely SHP626, LUM002 or SAR548304B)
Mirum Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2020-003027-41-DE Canada;Germany;Israel;United Kingdom;United States;
Volixibat potassium
Mirum Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2020-003027-41-DE Canada;Germany;Israel;United Kingdom;United States;
Xifaxan
Mayo Clinic
2012 Phase 1 NCT01695174 United States;
[18F]FP-R01-MG-F2
Stanford University
2017 Early Phase 1 NCT03183570 United States;